Method for determining the efficacy or sensitivity of anti-transferrin receptor antibodies

Intracellular iron levels serve as an indicator for determining the efficacy of anti-transferrin receptor antibodies, enabling effective treatment assessment in conditions like acute myeloid leukemia.

JP7875530B2Active Publication Date: 2026-06-18NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST +1
9 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST
Filing Date
2021-10-08
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

There is a lack of methods to determine the efficacy or sensitivity of anti-transferrin receptor antibodies, which are useful in treating diseases such as cancer.

⚗Method used

Intracellular iron levels are used as an indicator to assess the efficacy or sensitivity of anti-transferrin receptor antibodies, with lower iron levels indicating higher drug efficacy.

🎯Benefits of technology

This method allows for the determination of anti-transferrin receptor antibody efficacy, particularly in treating blood cancers like acute myeloid leukemia, by measuring intracellular iron levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention addresses the problem of providing a method for determining the sensitivity or medicinal effect of an anti-transferrin receptor antibody. The present invention provides a method that is for determining the sensitivity or medicinal effect of an anti-human transferrin receptor antibody having an effect of inhibiting binding between human transferrin and a human transferrin receptor, and that uses the amount of intracellular iron as an index.
Need to check novelty before this filing date? Find Prior Art